Release
📈 Stocks
TransCode Therapeutics Explores Strategic Alternatives for Lead Oncology Asset
(just now)
Boston-based TransCode Therapeutics is seeking strategic partners or a potential sale for its lead oncology asset, TTX-MC138, currently in Phase 2a clinical…